[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia":41},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,122,0,25,[9,66,100,129,158,188,207,235,268,290,316,343,369,391,423,446,473,503,552,579,602,629,654,678,706],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878",false,"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"ALL","0 Years","20 Years",{"count":23,"type":24},5000,"ESTIMATED","OBSERVATIONAL","The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome","RECRUITING","2026-08-20",{"date":56,"type":57},"2026-08-21","ACTUAL",{"date":59,"type":57},"2020-03-05",{"date":61,"type":24},"2026-12",{"name":63,"class":64},"Duke University","OTHER",52,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":18,"sex":19,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":4,"leadSponsor":96,"locationsCount":99},"100058416","natural-history-management-and-genetics-of-the-hyperimmunoglobulin-e-recurrent-infection-syndrome-hies-100058416","NCT00006150","Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)","* INCLUSION CRITERIA:\n\nPatients may be included in this study who:\n\n* Were referred to the NIH with a diagnosis or a suspicion of Hyper IgE syndrome.\n* Are patients referred for other immune syndromes that demonstrate some of the characteristics of HIES.\n\n  * \\>=1 month for affected subjects\n  * Aged \\>=2 years for unaffected subjects\n* For unaffected subjects, are able to understand and have the willingness to sign a written informed consent document.\n\nUnaffected biological relatives of HIES patients are also eligible to enroll in a separate relative cohort.\n\nEXCLUSION CRITERIA:\n\nCoronary CTA will not be performed on any patient younger than 30 years or with contraindication to IV contrast media. This includes patients with 1) creatinine value of \\>1.3 mg\u002FdL, 2) history of multiple myeloma, 3) Use of metformin-containing products less than 24 hours prior to contrast media, and 4) history of significant allergic reaction to CT contrast agents despite the use of premedication.\n\nSubjects with a medical, psychiatric, or social condition which, in the opinion of the investigator, would place undue burden on the subject, NIH resources, or increase risk of participation, may be excluded.","1 Month","120 Years",{"count":75,"type":24},600,"The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections. Autosomal dominant Hyper IgE syndrome (AD-HIIES; Job's syndrome) is caused by STAT3 mutations, and is a multi-system disorder with skeletal, vascular, and connective tissue manifestations. Understanding how STAT3 mutations cause these diverse clinical manifestations is critical to our complete understanding of bone metabolism, bronchiectasis, dental maturation, and atherosclerosis. Bi-allelic mutations in DOCK8 cause a combined immunodeficiency previously described as autosomal-recessive Hyper IgE syndrome. These individuals suffer from extensive viral infections as well as have a high incidence of malignancy and mortality. The pathogenesis of this disease and long-term natural history is being investigated. Therefore, we seek to enroll patients and families with a confirmed or suspected diagnosis of HIES syndrome for extensive phenotypic and genotypic study as well as disease management. Patients will be carefully examined by a multidisciplinary team and followed longitudinally. Through these studies we hope to better characterize the clinical presentation of STAT3-mutated HIES, DOCK8 deficiency and other causes of the hyper IgE phenotype, and to be able to identify further genetic etiologies, as well as understand the pathogenesis of HIES. We seek to enroll 300 patients and 300 relatives....",[78,41,79,80,81],"Infections","Immune System Diseases","STAT3 Transcription Factor","Job Syndrome",[83,84,85,86,87,88,89,90],"DOCK8 Deficiency","PGM3 Deficiency","STAT3 Mutation","Job's Syndrome","Immunodeficiency","Natural History","Hyperimmunologobulin E Syndrome","HIE Syndrome","2026-08-15",{"date":93,"type":57},"2026-08-18",{"date":95,"type":57},"2000-08-10",{"name":97,"class":98},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":19,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":4,"leadSponsor":127,"locationsCount":99},"100063668","study-of-lung-proteins-in-patients-with-pneumonia-100063668","NCT00077909","Study of Lung Proteins in Patients With Pneumonia","Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates","* INCLUSION CRITERIA:\n* All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study.\n* A parent\u002Fguardian may provide consent for a child age 17 or under and a Legally Authorized Representative (LAR) may provide consent for adults unable to consent.\n\nEXCLUSION CRITERIA:\n\nPatients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded.","3 Years","99 Years",{"count":110,"type":24},750,"This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease. Pneumonia is a condition that causes lung inflammation AND is often caused by an infection. It is usually diagnosed by lung x-rays and listening to the chest with a stethoscope. This method can diagnose pneumonia, but it does not provide information on the cause of the inflammation - information that might be helpful in guiding treatment. This study will measure proteins in the lungs of patients to see if certain proteins are associated with specific forms of pneumonia, and can thus serve as biomarkers for disease.\n\nPatients undergoing diagnostic bronchoscopy at the NIH Clinical Center may participate in this study. Patients will undergo bronchoscopy and bronchoalveolar lavage as scheduled for their medical care. For this procedure, the patient's mouth and throat are numbed with lidocaine; a sedative may be given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully. Saline (salt water) is then injected through the bronchoscope into the air passage, acting as a rinse. A sample of fluid is then withdrawn for microscopic examination. Researchers in the current study will use some of the fluid obtained from the lavage to examine for protein content.\n\nIn addition to the bronchoscopy and bronchoalveolar lavage, participants will have about 2 tablespoons of blood drawn to compare blood test results with the results of the lung washings. Patients' medical records will be reviewed to obtain information on past medical history, current medical treatment, vital signs, and results of x-ray tests.\n\n...",[41,113,114],"Pulmonary Disease","Lung Disease",[116,117,41,118,119,88,120,113,121],"Proteomics","Infection","Mass Spectrometry","BAL","Lung","Lung Infiltrates","2026-08-14",{"date":124,"type":57},"2026-08-17",{"date":126,"type":57},"2004-02-20",{"name":128,"class":98},"National Institutes of Health Clinical Center (CC)",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":140,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":99},"100627848","efficacy-and-safety-of-intrapulmonary-percussive-ventilation-in-patients-with-pulmonary-infection-receiving-invasive-mechanical-ventilation-100627848","NCT07453966","Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation","Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation Assessed by Electrical Impedance Tomography: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Meeting the diagnostic criteria for pulmonary infection, defined as follows: meeting the diagnostic criteria for hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) according to the Chinese Guidelines for the Diagnosis and Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults (2018 edition), or meeting the diagnostic criteria for community-acquired pneumonia (CAP) according to the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults (2016 edition);\n3. Oxygenation index (PaO₂\u002FFiO₂) ≤ 300;\n4. Currently receiving invasive mechanical ventilation, with no planned liberation from invasive mechanical ventilation within the next 24 hours;\n5. Receiving analgesia and sedation;\n6. Written informed consent provided by the patient's family member or legally authorized representative.\n\nExclusion Criteria:\n\n1. Presence of severe hemodynamic instability (norepinephrine dose \\> 0.5 μg\u002Fkg\u002Fmin);\n2. Markedly elevated intracranial pressure (\\> 25 mmHg) or a condition requiring strict intracranial pressure control;\n3. Severe pulmonary bullae, untreated tension pneumothorax or undrained mediastinal emphysema;\n4. Unstable chest wall, flail chest, recent thoracic or airway surgery, or severe thoracic spine injury;\n5. Active massive hemoptysis;\n6. Severe bronchospasm or inability to tolerate fluctuations in airway pressure;\n7. Inability to place the EIT chest belt, such as open thoracic surgical wounds or skin lesions at the belt placement site;\n8. Receiving extracorporeal membrane oxygenation (ECMO);\n9. Acute exacerbation of chronic obstructive pulmonary disease as the primary reason for the current episode of invasive mechanical ventilation;\n10. Expected death within 24 hours, or a decision already made to withhold or withdraw life-sustaining treatment;\n11. Pregnancy or breastfeeding;\n12. Concurrent participation in another clinical trial.","18 Years",{"count":138,"type":24},110,"INTERVENTIONAL",[141],"NA","The goal of this clinical trial is to learn whether adding intrapulmonary percussion ventilation (IPV) to standard airway clearance treatment improves clinical outcomes in invasively mechanically ventilated patients with pulmonary infection. It will also evaluate the safety of IPV in this population and assess changes in lung ventilation using electrical impedance tomography (EIT).\n\nThe main questions it aims to answer are:\n\nDoes adding IPV shorten the duration of invasive mechanical ventilation compared with standard therapy alone? Does IPV improve regional and global lung ventilation? Does IPV improve clinical indicators, including oxygenation, lung mechanics, and pulmonary infection scores? Is IPV safe in mechanically ventilated patients with pulmonary infection?\n\nParticipants will:\n\nReceive either standard therapy alone or standard therapy plus IPV Undergo serial EIT monitoring at predefined time points Receive routine clinical assessments and ventilator parameter monitoring during ICU stay Be followed until successful weaning, discharge, or completion of hospitalization",[41],[41,145,146,147,148],"Intrapulmonary percussion ventilation","mechanical ventilation","electrical impedance tomography","pulmonary infection","2026-08-10",{"date":151,"type":57},"2026-08-12",{"date":153,"type":57},"2026-03-06",{"date":155,"type":24},"2027-05-01",{"name":157,"class":64},"Zhongnan Hospital",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":19,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":139,"phases":169,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":99},"100554125","how-omt-benefits-newly-diagnosed-patients-with-respiratory-illness-when-given-alongside-other-standard-care-100554125","NCT06495021","How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.","OMT and Respiratory Illness","Inclusion Criteria:\n\n* Patients being seen for respiratory illness symptoms at Geisinger 65-Forward Buckhorn, PA clinic for care.\n* Patients age of 65-100\n* New diagnosis of upper respiratory illness, sinusitis, bronchitis, or pneumonia during outpatient visit.\n\nExclusion Criteria:\n\n* Patients that have a healing fracture, including the spine, pelvis, shoulder, ribs, vertebrae, or extremities.\n* Patients actively receiving any type of cancer treatment\n* Patients with active or previously diagnosed liver disease.","65 Years","100 Years",{"count":168,"type":24},68,[141],"This study is to see Osteopathic Manipulative Therapy, or OMT, can aid in treating patients being seen for respiratory illness and associated symptoms. The hypothesis is that the addition of OMT therapy, alongside other standard care (such as a medication), can help lessen patient symptoms sooner than just other treatment alone, and the duration of the condition will shorten as well.",[41,172,173,174,175],"Sinusitis","Bronchitis","Respiratory Disease","Respiratory Tract Infections",[177,178,179],"Osteopathic Manual Therapy","Respiratory Illness","OMT",{"date":181,"type":57},"2026-08-11",{"date":183,"type":57},"2024-12-31",{"date":185,"type":24},"2027-05-31",{"name":187,"class":64},"Geisinger Clinic",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":18,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":99},"100442419","hyperpolarized-129-xenon-imaging-in-adult-hematopoietic-cell-transplant-recipients-with-pulmonary-impairment-100442419","NCT05041140","Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment","Inclusion Criteria:\n\n\\- Allo-HCT recipients who are at least 18 years of age and have BOS (n=10 patients), BOS 0p (n = 10 patients), or cGVHD of a non-lung organ without evidence of pulmonary impairment (n = 5 patients).\n\nHealthy Cohort - Inclusion Criteria:\n\nWe will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis.\n\nExclusion Criteria:\n\n1. Participants unable to follow up at MD Anderson for routine clinical care\n2. Inability or unwillingness to give informed consent\n3. Relapsed disease or life expectancy less than 6 months at time of enrollment\n4. Severe claustrophobia precluding MRI imaging\n5. Active pulmonary infection\n6. Pregnant women",{"count":7,"type":24},"This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD).\n\nThe primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.\n\nA secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.",[197,41,198],"Pulmonary","Hematopoietic System--Cancer","2026-08-07",{"date":149,"type":57},{"date":202,"type":57},"2024-08-14",{"date":204,"type":24},"2027-07-20",{"name":206,"class":64},"M.D. Anderson Cancer Center",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":19,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":139,"phases":217,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":99},"100651483","effects-of-buteyko-breathing-versus-incentive-spirometry-on-oxygen-saturation-dyspnoea-exercise-tolerance-and-sputum-clearance-in-patients-with-smog-induced-pneumonia-100651483","NCT07759583","Effects of Buteyko Breathing Versus Incentive Spirometry on Oxygen Saturation, Dyspnoea, Exercise Tolerance, and Sputum Clearance in Patients With Smog Induced Pneumonia","Inclusion Criteria:\n\nMale and female participants Age between 25-40 years Clinically diagnosed pneumonia Recent exposure to high air pollution levels (AQI threshold exceeded within the past 7 days) Resting oxygen saturation between 86-95% Ability to understand and perform breathing exercises -\n\nExclusion Criteria:\n\nRequirement for mechanical ventilation or ICU admission Hemodynamic instability Severe chronic respiratory disease such as COPD with hypercapnia Pneumothorax or massive hemoptysis Recent thoracic surgery or trauma Cognitive impairment affecting cooperation Pregnancy\n\n\\-","25 Years","40 Years",{"count":216,"type":24},62,[141],"The current study will be a single-blind, parallel-group randomized controlled trial involving 62 patients diagnosed with smog-induced pneumonia. The study will compare the effects of Buteyko Breathing Technique (BBT) with Incentive Spirometry (IS) on respiratory outcomes.\n\nParticipants will be randomly assigned to two groups using a concealed allocation method. The experimental group will receive Buteyko Breathing Technique along with standard medical care, while the control group will receive Incentive Spirometry along with standard medical care.\n\nBoth interventions will be performed twice daily for approximately 20-30 minutes per session for seven days or until hospital discharge.\n\nPrimary outcomes will include oxygen saturation (SpO₂), dyspnoea severity, exercise tolerance, sputum clearance, and respiratory symptom burden. Assessments will be conducted at baseline (Day 0), mid-intervention (Day 3), post-intervention (Week 2), and follow-up (Week 4).\n\nThe study will be conducted at the pulmonary wards of Combined Military Hospital (CMH) and The Indus Hospital, Lahore.\n\nThe hypothesis is that Buteyko Breathing Technique may produce greater improvements in oxygen saturation, dyspnoea reduction, exercise tolerance, and sputum clearance compared with Incentive Spirometry in patients with smog-induced pneumonia.",[220,41],"Smog-Induced Pneumonia",[222,223,224,225,226],"Buteyko Breathing Technique","Incentive Spirometry","Oxygen saturation","Pulmonary Rehabilitation","Smog-induced Pneumonia","2026-08-06",{"date":151,"type":57},{"date":230,"type":57},"2026-05-01",{"date":232,"type":24},"2026-10-15",{"name":234,"class":64},"Lahore University of Biological and Applied Sciences",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":19,"minAge":165,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":139,"phases":243,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":99},"100633704","phase-3-comparative-efficacy-and-safety-of-propofol-ketamine-combination-versus-propofol-monotherapy-in-geriatric-patients-under-invasive-ventilation-100633704","NCT07530146","Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Admitted to ICU with a diagnosis of infection (sepsis, septic shock, or pneumonia)\n* Known history of cardiac disease (e.g., ischemic heart disease, heart failure, arrhythmias)\n* Requiring endotracheal intubation for airway protection or respiratory failure\n* Informed consent obtained from patient or legal representative\n* Patient NOT on sedation prior randomization.\n\nExclusion Criteria:\n\n* Known allergy or contraindication to propofol or ketamine\n* Severe hepatic or renal dysfunction (Child-Pugh C, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Uncontrolled hypertension (SBP \\> 180 mmHg or DBP \\> 110 mmHg)\n* Intracranial pathology (e.g., raised intracranial pressure, recent stroke, brain tumor)\n* Ongoing use of other sedative or anesthetic agents within 12 hours prior to intubation\n* Do-not-intubate or do-not-resuscitate orders\n* Participation in another interventional trial within the last 30 days\n* History of Psychosis\n* Severe Organ Dysfunction: Patients with Child-Pugh C hepatic failure\n* • Severe hypotension despite vasopressor therapy (systolic blood pressure \\\u003C 100 mmHg or diastolic blood pressure \\\u003C 70 mmHg)",{"count":242,"type":24},41,[244],"PHASE3","The study is a prospective randomized controlled trial comparing the efficacy and safety of propofol-ketamine (\"Ketofol\") versus propofol monotherapy in geriatric ICU patients. Eligible participants are critically ill elderly patients with a history of cardiac disease who require endotracheal intubation and have not yet received sedation. The investigators focus on a specific population in which geriatric patients have different pharmacokinetics and pharmacodynamics and are more prone to side effects than other populations.\n\nPrimary outcome: Incidence of hemodynamic instability (defined as hypotension requiring vasopressors), measured by mean arterial pressure (MAP) at baseline, during intubation, and post-intubation at 1, 5, 10, 30, and then every 8h for 24 hours.",[247,248,41],"The Critically Ill Patient is Requiring Intubation","Septic Shock",[250,251,252,253,254,255,256,257,258],"ketofol","propofol","septic shock","pneumonia","geriatric","elderly","critical ill","ICU patient","intubation","2026-07-19",{"date":261,"type":57},"2026-07-21",{"date":263,"type":57},"2026-05-13",{"date":265,"type":24},"2026-10",{"name":267,"class":64},"Helwan University",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":99},"100647462","preadmission-glp-1-receptor-agonist-plus-sglt2-inhibitor-use-and-early-outcomes-after-pneumonia-hospitalization-in-adults-with-type-2-diabetes-100647462","NCT07708610","Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes","Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Type 2 diabetes mellitus\n* Hospitalization with pneumonia during the study period, serving as the index admission\n* Prescription of a GLP-1 receptor agonist, an SGLT2 inhibitor, or usual-care glucose-lowering therapy in the year before the index admission\n* No GLP-1 receptor agonist or SGLT2 inhibitor prescription in the 6 months before the first qualifying prescription\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus, or other specified diabetes types that are not type 2 diabetes\n* Human immunodeficiency virus infection\n* Bariatric surgery\n* Solid-organ transplantation\n* Pneumonia hospitalization, invasive mechanical ventilation, or renal replacement therapy in the year before the index admission\n* End-stage kidney disease, dialysis dependence, ventilator dependence, or tracheostomy status\n* Metastatic malignancy, lung cancer, or palliative care\n* Viral pneumonia, influenza with pneumonia, or COVID-19 around the index admission\n* Acute cardiovascular event in the 6 months before the index admission",{"count":276,"type":24},71775,"This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.",[41,279],"Type 2 Diabetes Mellitus (T2DM)","NOT_YET_RECRUITING","2026-07-13",{"date":283,"type":57},"2026-07-16",{"date":285,"type":24},"2026-07-31",{"date":287,"type":24},"2026-08-31",{"name":289,"class":64},"Chung Shan Medical University",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":139,"phases":298,"briefSummary":299,"conditions":300,"keywords":305,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":99},"100628577","effectiveness-of-chatbot-for-improving-caregiving-outcomes-in-primary-caregivers-of-geriatric-pneumonia-patients-a-study-on-knowledge-attitude-and-practice-100628577","NCT07463443","Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Study on Knowledge, Attitude and Practice.","Inclusion Criteria:\n\n* (1)Patients with a primary diagnosis of pneumonia during the current hospitalization.(2)Patients aged 65 years or older.(3)Primary caregivers aged 18 years or older.(4)Primary caregivers who can read and understand Mandarin Chinese.(5)Primary caregivers who own a mobile device (e.g., smartphone or tablet) and can use the chatbot application.\n\nExclusion Criteria:\n\n* (1)Primary caregivers who do not live with the patient.(2)Primary caregivers who have received formal training as professional nursing assistants or caregivers.(3)Primary caregivers who are currently or were formerly healthcare professionals (e.g., physicians, nurses, therapists).(4)Primary caregivers who do not possess a mobile device or are unable to use chatbot applications.",{"count":297,"type":24},150,[141],"Pneumonia is a leading cause of death and hospitalization among the elderly in Taiwan. High-quality home care is essential to recovery and reducing readmission, yet primary caregivers often lack the specific skills needed, such as airway clearance and safe feeding techniques. Traditional education, consisting of one-time verbal instructions and paper brochures, often lacks interactivity and real-time support.\n\nThis study introduces \"Pneumonia Care Helper,\" an interactive LINE chatbot designed to provide digital health education. The goal is to evaluate whether this digital tool is more effective than traditional paper-based education in improving the knowledge, attitudes, and caregiving practices of primary caregivers of elderly pneumonia patients. The study will compare the outcomes of caregivers using the chatbot versus those receiving standard paper-based instructions over a 5-day intervention period.",[41,301,302,303,304],"Family Caregivers","Knowledge, Attitudes, Practice","Chatbot","Geriatric Patient",[41,301,302,303,306],"Geriatric patient",{"date":308,"type":57},"2026-07-15",{"date":310,"type":57},"2026-03-13",{"date":312,"type":24},"2027-02-24",{"name":314,"class":315},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":19,"minAge":107,"maxAge":136,"enrollmentInfo":322,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":99},"100531568","prospective-multicentre-study-on-symptoms-in-first-onset-bronchial-asthma-in-children-and-adolescents-100531568","NCT06201494","Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents","Inclusion Criteria:\n\n\\- Child 3 - 18 years old, first evaluation in pulmonary outpatient clinic for any of the following respiratory symptoms: cough, shortness of breath, chest tightness, wheezing, recurrent lower respiratory tract and lung infections, dyspnoea of any type, pathological listening findings.\n\nExclusion Criteria:\n\n* Other documented chronic respiratory, cardiovascular, neurological, genetic, infectious, metabolic disease, significant immaturity or other disease that may be accompanied by respiratory symptoms.",{"count":323,"type":24},80,"Bronchial asthma may present with symptoms other than the commonly reported complaints (cough, chest tightness, shortness of breath and wheezing). Less common symptoms include chronic or recurrent productive cough, inspiratory dyspnoea or recurrent pneumonia. Children presenting with these symptoms are often diagnosed with asthma bronchiale and benefit from antiasthmatic management.",[326,44,327,328,41,329,330,331,332,333,334],"Asthma","Dyspnea","Cough","Wheezing","Shortness of Breath","Chest Tightness","Lower Respiratory Tract and Lung Infections","Recurrent Respiratory Tract Infections","Mucus; Plug",{"date":336,"type":57},"2026-07-14",{"date":338,"type":57},"2023-01-01",{"date":340,"type":24},"2027-06-01",{"name":342,"class":64},"Charles University, Czech Republic",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":19,"minAge":350,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":139,"phases":354,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":367,"locationsCount":4},"100643415","phase-4-the-lalelalung-study-digital-stethoscope-clinical-evaluation-100643415","NCT07631377","The LalelaLung Study: Digital Stethoscope Clinical Evaluation","LaLeLa","Inclusion Criteria:\n\n* Age 2 to 59 months at the time of screening\n* Presence of cough and\u002For difficulty breathing\n* No WHO-defined emergency\u002Fdanger signs (e.g., grunting, cyanosis, apnea, convulsions, or altered level of consciousness)\n* A legal caregiver is present, able to understand the study information, and willing to provide written informed consent\n* Caregiver is willing and able to provide contact information (e.g., mobile phone number) to allow 7-day follow-up after the clinic visit\n\nExclusion Criteria:\n\n* Presence of WHO-defined emergency signs requiring immediate referral or hospital admission (grunting, cyanosis, apnea, uncompensated shock, convulsions, diarrhea with severe dehydration, or altered level of consciousness)\n* Critical illness or clinical instability judged by the screening clinician or study physician to require urgent medical attention\n* Age outside the target range (younger than 2 months or older than 59 months)\n* Previous enrollment in the study\n* Refusal or withdrawal of informed consent by the legal caregiver at any time prior to randomization","2 Months","59 Months",{"count":353,"type":24},350,[355],"PHASE4","Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries. In these settings, frontline health workers diagnose pneumonia using the World Health Organization's Integrated Management of Childhood Illness (IMCI) guidelines, which rely mainly on counting how fast a child is breathing and checking for chest indrawing. This approach has saved many lives, but it is not very specific. As a result, many children who actually have self-limiting viral illnesses that do not require antibiotics are nonetheless treated with antibiotics, contributing to the global rise of antimicrobial resistance.\n\nNew digital stethoscopes paired with artificial intelligence (AI) can record a child's lung sounds and automatically detect abnormal sounds such as crackles and wheezes with accuracy comparable to physicians. The LaLeLa Lung Study will evaluate whether adding an AI-enabled digital stethoscope to standard IMCI assessment improves the accuracy of pneumonia diagnosis among children aged 2 to 59 months who present with cough and\u002For difficult breathing at a primary care clinic in Cape Town, South Africa.\n\nThe main component (Objective 1) is a randomized, triple-blinded diagnostic accuracy study that will enroll 350 children, randomly assigned in a 1:1 ratio to either IMCI care enhanced by the AI-enabled digital stethoscope or standard IMCI care. An independent panel of physicians, blinded to the AI results and to study-arm assignment, will review each case and serve as the reference standard for determining whether pneumonia was truly present. The investigators hypothesize that IMCI enhanced by the AI stethoscope will diagnose pneumonia more accurately, and target antibiotics more appropriately, than standard IMCI alone. Nested sub-studies will additionally evaluate a second AI stethoscope for tuberculosis detection, a wearable lung-sound and respiratory-rate patch, an automated respiratory-rate monitor, and a smartphone-connected pulse oximeter.\n\nA separate component (Objective 2) is a mixed-methods implementation study at a second clinic that will assess how easily health workers can use these devices, how acceptable the devices are to health workers and caregivers, and how well the devices fit into routine clinic workflows.\n\nThroughout the study, all AI-generated results will remain concealed from clinic staff, study clinicians, and caregivers, so the AI-generated results will not influence the care any child receives. All children continue to receive standard IMCI care. Findings will help inform whether AI-enabled digital auscultation should be integrated into childhood pneumonia care in South Africa and similar low-resource settings, with the goal of improving diagnosis, strengthening antibiotic stewardship, and reducing antimicrobial resistance and child mortality.",[41,358,175,359,360,361],"Tuberculosis, Pulmonary","Bronchiolitis","Respiratory Sounds","Antibiotic Resistant Strain","2026-07-10",{"date":281,"type":57},{"date":124,"type":24},{"date":366,"type":24},"2028-06-30",{"name":368,"class":64},"Johns Hopkins University",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":376,"targetDuration":378,"studyType":25,"phases":4,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":389,"locationsCount":4},"100645581","pilot-study-to-study-the-time-between-pleuropulmonary-ultrasound-and-antibiotic-therapy-prescription-in-patients-admitted-to-the-emergency-department-for-suspected-pneumonia-100645581","NCT07703852","Pilot Study to Study the Time Between Pleuropulmonary Ultrasound and Antibiotic Therapy Prescription in Patients Admitted to the Emergency Department for Suspected Pneumonia","PRE-EPPA","Inclusion Criteria:\n\n* Patient over 18 years admitted the the emergency department of Grenoble Alpes University Hospital with respiratory symptoms (cough and\u002For dyspnea, fever).\n* No objection by the subject to the study\n* Affiliated to the french social security system (or equivalent)\n\nExclusion Criteria:\n\n* Patient admitted to a life-threatening emergency\n* Patient already on antibiotic therapy on admission\n* Patient excluded from another study\n* Patient with respiratory signs following chest trauma\n* Unable to communicate or non-french speaking patients or those with impaired comprehension or consciousness\n* Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)\n* The patient already enrolled in the study",{"count":377,"type":24},15,"1 Day","Pneumonia is a common pathology with significant morbidity and mortality. It is recommended in his diagnostic approach to perform either a chest X-ray or a pleuropulmonary ultrasound. Previous studies have shown the advantages of ultrasound in terms of diagnostic performance cost and patient irradiation. However, it remains little used in clinical practice.",[41],[41,382,383],"Pleuropulmonary ultrasound","Antibiotic","2026-07-09",{"date":336,"type":57},{"date":281,"type":24},{"date":388,"type":24},"2026-09-30",{"name":390,"class":64},"University Hospital, Grenoble",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":139,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":99},"100569296","the-effects-of-endotracheal-suctioning-on-pain-and-serum-markers-100569296","NCT06692400","The Effects of Endotracheal Suctioning on Pain and Serum Markers","The Impact of Endotracheal Suctioning on Pain, Hypoxia, and Oxidative Stress Biomarkers in Intubated Adult ICU Patients: A Controlled Trial","Inclusion Criteria:\n\n* Adults (aged 18 years and older)\n* Current diagnosis of flu, pneumonia, COVID, or sepsis\n* Intubated and receiving mechanical ventilation.\n* Have arterial lines placed\n* Require endotracheal suctioning as part of their care\n\nExclusion Criteria:\n\n* Patients receiving neuromuscular blocking agents\n* Contraindications for blood draws (hemoglobin levels below 8.0 g\u002FdL; Jehovah's Witness)",{"count":138,"type":24},[141],"The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress.\n\nThe main questions this study aims to answer are:\n\nDoes ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress.\n\nParticipants will:\n\nHave pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning.\n\nProvide demographic information (like age, gender, and diagnosis) from medical records.\n\nThis research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.",[402,403,404,405,406,407,408,409,410,411,412,413,414,415,41],"Intensive Care Unit ICU","Intubation","Critical Illness","Mechanical Ventilation","Pain Measurement","Pain, Procedural","Oxidative Stress","Hypoxia","Biomarkers \u002F Blood","Adult","Uric Acid","Sepsis","COVID","Influenza","2026-07-08",{"date":362,"type":57},{"date":419,"type":57},"2025-01-30",{"date":61,"type":24},{"name":422,"class":64},"Loma Linda University",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":139,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":445},"100642234","self-directed-mobile-mindfulness-to-address-icu-survivors-psychological-distress-100642234","NCT07634419","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress: Lift RCT (Lift 3)","Lift 3","Inclusion Criteria:\n\nInclusion criteria present during hospitalization\n\n1. Adult (age ≥18)\n2. Managed in an ICU for ≥24 hours during the time inclusion criterion #3 is met\n3. Serious acute cardiorespiratory condition, defined as ≥1 of the following:\n\n   * mechanical ventilation via endotracheal tube for ≥4 hours\n   * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure\n   * new use of supplemental oxygen ≥6 liters per minute (or increase in baseline continuous oxygen)\n   * use of vasopressors for shock of any etiology\n   * use of inotropes for shock of any etiology\n   * use of pulmonary vasodilators\n   * use of aortic balloon pump or cardiac assist device for cardiogenic shock\n   * use of diuretic intravenous drip\n   * evidence of acute coronary ischemia (i.e., elevated troponin level, supporting EKG changes, unstable angina symptoms documented)\n   * urgent cardiac catheterization\n4. Cognitive status intact\n\n   o No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart\n5. Absence of severe and\u002For persistent mental illness\n\n   o Treatment for severe and\u002For persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \\[as per medical record\\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission\n6. Functional fluency in English or Spanish (i.e., sufficient knowledge of English or Spanish to complete study tasks like watch videos, complete surveys)\n\nInclusion criteria present after hospital discharge (i.e., at the time of arrival home after discharge from the hospital):\n\n1\\. Elevated baseline psychological distress symptoms, defined as a PHQ-9 score ≥5\n\nExclusion Criteria:\n\nExclusion criteria present in the hospital:\n\n1\\. Discharged to a location other than a home setting (e.g., nursing home, long-term acute care facility, inpatient rehabilitation facility)\n\nExclusion criteria present after hospital discharge (i.e., at T1 Data Collection conducted at the time of arrival home from the hospital):\n\n1. Severe psychological distress as assessed by endorsement of active suicidality (see Protection of Human Subjects document for study team management of this finding)\n2. Failure to randomize within 1 month after discharge from the hospital to home\n3. Failure to login to study app and access content within 2 weeks after randomization",{"count":432,"type":24},450,[141],"Serious acute heart and lung illnesses like heart failure, severe COVID, and sepsis often leave survivors struggling not only physically, but also with lasting depression, anxiety, and stress. These problems that are hard to treat because access to mental health care is often limited. To help address this, the researchers created Lift, a fully automated mindfulness program designed with patient input and delivered through a mobile app. The investigators now plan a large, multi-site study to test whether Lift improves mental health and quality of life over six months compared to a critical illness education program called Enlighten Recovery. Overall the goal is to make an easy-to-use, widely accessible program available to people across the U.S., including those who speak Spanish.",[404,37,413,436,41,437],"Ards","Trauma Injury","2026-07-07",{"date":416,"type":57},{"date":441,"type":24},"2027-01-01",{"date":443,"type":24},"2031-05-31",{"name":63,"class":64},3,{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":139,"phases":455,"briefSummary":456,"conditions":457,"keywords":462,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":445},"100631957","optimizing-medications-and-lung-health-in-people-with-hiv-through-pharmacist-led-proactive-e-consults-100631957","NCT07507435","Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults","Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)","Inclusion Criteria:\n\n* PWH on ART for 6 months, receiving care at the VA, and one or more of the following:\n\n  1. Actively smoking\n  2. Prescribed ICS for \\>90 days\n  3. Prescribed a PPI for \\>90 days\n\n     Exclusion Criteria:\n* Enrolled in palliative care or hospice\n* if a non-VA provider is the main primary care or HIV provider\n* Are currently participating in a separate ongoing interventional clinical trial",{"count":454,"type":24},480,[141],"People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs).\n\nOPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate.\n\nThe trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.",[458,459,460,461,41],"HIV","Inhaled Corticosteroid","Proton Pump Inhibitor","Smoking Cessation",[463,464,458],"Pharmacist","E-consult","2026-07-06",{"date":438,"type":57},{"date":468,"type":24},"2026-08",{"date":470,"type":24},"2029-09",{"name":472,"class":64},"Seattle Institute for Biomedical and Clinical Research",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":484,"conditions":485,"keywords":489,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":445},"100522799","evaluation-of-a-multi-country-medical-oxygen-program-100522799","NCT06087315","Evaluation of a Multi-country Medical Oxygen Program","Realist Evaluation and Learning in a Multi-country Medical OXYgen Program (REAL-MOXY)","REAL-MOXY","Sub-study 1:\n\nResearch Question: What are the baseline pulse oximetry and oxygen practices for children admitted to participating health facilities, and what is the level of institutional readiness for oxygen service delivery? Which facilities, representative of high- and low-performing facilities and different levels of care and facility types, can be selected for additional investigation to understand current functioning of oxygen systems?\n\nSetting and Population: The broader MOXY program baseline cross-sectional assessments involve 9 countries. We have selected 6 MOXY countries for the mixed methods studies outlined in this protocol - Nigeria, Uganda, Liberia, Rwanda, Cambodia and Lao PDR - based on pre-existing research collaborations, and with the aim of representing broadly different geographical contexts.\n\nBaseline assessments are being conducted in all facilities participating in the MOXY program in each of the 6 study countries. From this data set, we will analyse primary and secondary outcomes for wards caring for children \\\u003C15 years (including neonatal wards where relevant).\n\nAnalysis\u002Foutcomes: Primary - proportion of admitted children (\\\u003C15 years, including neonates) screened with pulse oximetry. Secondary - proportion of admitted children with hypoxaemia (\\\u003C15 years, including neonates) treated with oxygen. For Real-Moxy the secondary outcome will inform identification of facilities for inclusion.\n\nSub-study 2:\n\nResearch question: Where and how are patients managed from arrival to admission and discharge (or transfer), and how does oxygen equipment move within and between clinical areas? How do process maps vary for different clinical scenarios representing different patient groups: i) pneumonia with and without hypoxaemia; ii) severe, acute illness syndrome with WHO emergency signs (e.g., shock, multi-trauma, seizures); iii) surgical condition and iv) neonatal illness (inborn and outborn)?\n\nSetting and Population: This will be conducted in 10 health facilities in each of the 6 countries (Nigeria, Uganda, Liberia, Rwanda, Lao PDR, Cambodia), selected to represent high and low functioning facility oxygen systems and include secondary and tertiary health facilities from government and non-governmental sectors (identified in sub-study 1). We will focus on admitted children (\\\u003C15 years, including neonates) with (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness. We have chosen these conditions to represent diagnoses with a high prevalence of hypoxaemia, and to capture the nuances of how pulse oximetry and oxygen practices are adapted (or not adapted) to clinical scenarios (e.g., having a lower threshold to provide oxygen to a patient in shock; or targeting safe oxygen saturations in neonates).\n\nAnalysis\u002Foutcomes: Facility maps of patient and equipment flow.\n\nSub-study 3:\n\nResearch question: What is the sequence of emergency care for an unwell child in the first 4 hours, and how are decisions made - particularly relating to oxygen (when to start, stop, how much, what delivery modality, etc.)? What are the points of delays to appropriate care (including pulse oximetry and oxygen) and at what points in time and location could pulse oximetry and oxygen be used better for emergency care of children?\n\nSetting and Population: facilities are same as sub-study 2). Children (\\\u003C15 years, including neonates) presenting with each of 4 acute illness syndromes: (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness.\n\nAnalysis\u002Foutcomes: Patient journey maps.\n\nSub-study 4:\n\nResearch question: How do healthcare workers use pulse oximetry and oxygen for admitted patients, and how does this change over time and vary between patient groups, facility type, and location? How do practices compare with treatment guidelines and where are the priority areas for improving oxygen care?\n\nPopulation and setting: Facilities are same as sub-studies 2\\&3.\n\nAnalysis\u002Foutcomes: Narrative descriptions of handover, ward rounds, and nursing rounds, with specific emphasis on how pulse oximetry is used, and decision making for oxygen therapy.\n\nSub-study 5: Indepth interviews and focus group discussions Research questions: 5a) How do patients\u002Fcaregivers perceive pulse oximetry and oxygen therapy within their broader care experience? 5b) How do healthcare workers, managers and technicians perceive oxygen therapy and the provision of oxygen-related care within the broader care provision experience?\n\nPopulation:\n\n* Patients and caregivers enrolled in sub-study 3 (patient journey mapping).\n* Healthcare workers (bedside), managers (including clinical and non-clinical managers) and technicians in each health facility. We will select staff with direct responsibility for wards caring for children \\\u003C15 years.\n\nAnalysis\u002Foutcomes: Reflexive thematic analysis of interviews and focus group discussions.","15 Years",{"count":483,"type":24},1200,"REAL-MOXY is a set of 5 mixed methods studies designed to understand how oxygen and pulse oximetry are used (or not used) at a facility level, to identify opportunities and barriers for strengthening oxygen systems for beneficiaries, users and managers.",[486,487,41,413,488],"Hypoxemia","Neonatal Disease","Morality",[490,491,492,493,494,495],"Oxygen systems","Pulse oximetry","Low middle income countries","Global health","Mixed-methods evaluation","Realist evaluation",{"date":416,"type":57},{"date":498,"type":57},"2023-11-27",{"date":500,"type":24},"2027-12",{"name":502,"class":64},"Murdoch Childrens Research Institute",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":510,"enrollmentInfo":511,"targetDuration":513,"studyType":25,"phases":4,"briefSummary":514,"conditions":515,"keywords":525,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":99},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390","NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","90 Years",{"count":512,"type":24},400,"30 Days","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[41,516,517,518,519,520,521,522,523,524],"Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[516,526,518,527,521,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","2026-06-26",{"date":545,"type":57},"2026-07-02",{"date":547,"type":57},"2025-11-13",{"date":549,"type":24},"2031-11-13",{"name":551,"class":64},"Azienda Ospedaliero-Universitaria Careggi",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":139,"phases":561,"briefSummary":563,"conditions":564,"keywords":565,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":578},"100637440","phase-2-a-clinical-trial-to-evaluate-agent-797-plus-standard-of-care-in-participants-with-severe-pneumonia-with-moderate-to-severe-acute-hypoxemic-respiratory-failure-100637440","NCT07615010","A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure","Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria","Key Inclusion Criteria:\n\n* Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion\n* Acute hypoxemic respiratory failure (AHRF)\n* Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria\n* Onset of severe pneumonia with AHRF ≤7 days prior to informed consent\n\nKey Exclusion Criteria:\n\n* More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent\n* Pregnancy or breastfeeding\n* History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative\n* Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":560,"type":24},90,[562],"PHASE2","This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).",[41],[566,567,568],"Acute Hypoxemic Respiratory Failure","AHRF","agenT-797","2026-06-25",{"date":543,"type":57},{"date":572,"type":57},"2026-05-26",{"date":574,"type":24},"2027-08",{"name":576,"class":577},"MiNK Therapeutics","INDUSTRY",4,{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":19,"minAge":585,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":139,"phases":588,"briefSummary":589,"conditions":590,"keywords":591,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":99},"100616659","ketogenic-approach-to-restore-muscle-in-older-patients-with-community-acquired-pneumonia---karma-p-trial-100616659","NCT07308483","Ketogenic Approach to Restore Muscle in Older Patients With Community-Acquired Pneumonia - KARMA-P Trial","Inclusion Criteria:\n\n* Age 55 years and older\n* Bacterial community-acquired pneumonia\n* Expected at least 10-day stay in the hospital\n* Ability to ingest food orally\n* Willingness to be randomized to either treatment group\n* Willingness to participate in all study procedures\n\nExclusion Criteria:\n\n* Failure to provide informed consent\n* Moribund\n* Vegetarian\u002Fvegan\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Diagnosed dementia\n* Hip fracture, hip or knee replacement, or spinal surgery within past 4 months\n* Simultaneous participation in another intervention trial","55 Years",{"count":587,"type":24},30,[141],"The purpose of the study is to see if a ketogenic diet compared to a standard diet is better to maintain muscle function and health in hospital admitted pneumonia patients.",[41],[592,253],"ketogenic feeding","2026-06-22",{"date":595,"type":57},"2026-06-24",{"date":597,"type":24},"2026-10-01",{"date":599,"type":24},"2029-07-31",{"name":601,"class":64},"University of Alabama at Birmingham",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":139,"phases":612,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":578},"100637274","early-phase-1-yiqi-huoxue-jiedu-formula-combined-with-bacteriophages-in-the-treatment-of-severe-pneumonia-100637274","NCT07612605","Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia","A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome;\n* Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa;\n* Aged 18 to 85 years old;\n* Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy;\n* Patients or their family members have fully read, understood and signed the informed consent form.\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating;\n* Patients with immunodeficiency;\n* Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases;\n* Patients who have received mechanical ventilation for more than 60 days prior to enrollment;\n* Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD);\n* Patients with incomplete sampling or clinical data;\n* Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula;\n* Patients judged by the researchers as unsuitable for participation in this study.","85 Years",{"count":611,"type":24},250,[613],"EARLY_PHASE1","Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.",[41],[617,618,619,41],"bacteriophage","Yiqi Huoxue Jiedu Formula","drug-resistant bacteria","2026-05-21",{"date":622,"type":57},"2026-05-29",{"date":624,"type":24},"2026-06-01",{"date":626,"type":24},"2029-12-31",{"name":628,"class":64},"Chinese PLA General Hospital",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":139,"phases":639,"briefSummary":640,"conditions":641,"keywords":642,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":652,"locationsCount":99},"100589121","early-phase-1-ino300-therapy-in-critically-ill-patients-with-pneumonia-100589121","NCT06950294","iNO300 Therapy in Critically Ill Patients With Pneumonia","High Dose Inhaled Nitric Oxide Therapy in Critically Ill Patients With Pneumonia: a Pilot, Double-blinded, Randomized, Controlled Trial","iNO300","Inclusion Criteria:\n\n* 18 years or older\n* Intubated and mechanically ventilated\n* Within 72h of diagnosis of community- or hospital-acquired pneumonia\n* Written informed consent obtained from patients or legally authorized representatives\n\nExclusion Criteria:\n\n* Baseline methemoglobin 3% or higher\n* Genetic diseases including glucose-6-phosphate dehydrogenase deficiency, cytochrome b5 reductase deficiency, sickle cell disease\n* Oxygen saturation \\\u003C 88% on 100% inspired fraction of oxygen\n* Anemia with hemoglobin \\\u003C 7.0 g\u002Fdl\n* Acute cardiogenic shock requiring inotropic or mechanical support with an ejection fraction less than 20%\n* Receiving inhaled NO therapy or decision to initiate inhaled NO therapy within 24 hours post randomization\n* A decision to do-not-resuscitate (DNR)\n* Enrollment in another experimental antimicrobial treatment protocol\n* Patients for whom follow-up is expected to be impossible",{"count":638,"type":24},34,[613],"The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to treat severely sick patients with pneumonia will be explored. Patients who are 18 years or older, newly diagnosed with pneumonia, and severely sick with requirement of a breathing machine could be included. The main questions it aims to answer are:\n\nHow does methemoglobin change through the iNO treatment? Does iNO therapy increase the number of patients recovering from pneumonia? Researchers will compare iNO treatment to placebo, which means using the same device as the treatment group without delivering the study drug.\n\nParticipants will:\n\n* Receive iNO treatment starting at 250 ppm, not exceeding 300 ppm, 40 min, every 6 hours, from day 1 to day 5\n* Be followed up for 60 days",[404,41],[643,41,644,645],"High dose inhaled nitric oxide","Critical care","Methemoglobin","2026-05-20",{"date":648,"type":57},"2026-05-22",{"date":650,"type":57},"2026-02-23",{"date":61,"type":24},{"name":653,"class":64},"Massachusetts General Hospital",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":664,"conditions":665,"keywords":668,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":99},"100637503","sulbactam-durlobactam-in-crab-infection-a-real-world-cohort-study-100637503","NCT07601711","Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study","This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis","SD-CRAB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:\n\n  1. patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or\n  2. transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy.\n* Treatment initiation time can be clearly determined.\n* Availability of clinical outcome data.\n\nExclusion Criteria:\n\n* Colonization without evidence of active infection.\n* Missing key clinical data.\n* Inability to determine treatment initiation time.\n* Pregnancy or lactation.\n* Patients considered unsuitable by investigators.",{"count":663,"type":24},200,"This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.\n\nThe primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.\n\nTo reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.",[666,667,41,413],"Carbapenem-Resistant Acinetobacter Baumannii Infection","Bloodstream Infection",[669],"CRAB Infection","2026-05-19",{"date":648,"type":57},{"date":673,"type":57},"2025-11-11",{"date":675,"type":24},"2027-11-11",{"name":677,"class":64},"Sichuan Provincial People's Hospital",{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":165,"enrollmentInfo":685,"targetDuration":4,"studyType":139,"phases":687,"briefSummary":688,"conditions":689,"keywords":692,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":698,"lastUpdatePostDateStruct":699,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":99},"100637232","phase-3-analysis-of-growth-differentiation-factor-15-gdf-15-mid-regional-proadrenomedullin-mr-proadm-and-persepsin-levels-in-patient-in-acute-coronary-syndrome-patients-with-pneumonia-with-or-without-influenza-vaccination-100637232","NCT07604103","Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination","Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination","Inclusion Criteria:\n\n* Adult male patients (\\\u003C 65 years old).\n* History of being an active smoker.\n* Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.\n* Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.\n* Willing to undergo all study procedures and sign the Informed Consent form.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components).\n* Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy.\n* Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values.\n* Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase.\n* Patient death before the observation period (up to post-vaccination) is completed.\n* Patient unilaterally resigns or withdraws consent during the study.\n* Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.",{"count":686,"type":24},60,[244],"The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations.\n\nThe main questions it aims to answer are:\n\n* Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients?\n* How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations.\n\nParticipants will:\n\n\\- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.",[690,41,691],"Acute Coronary Syndromes (ACS)","COPD (Chronic Obstructive Pulmonary Disease)",[693,694,695,696,41,697],"GDF-15","MR proADM","Persepsin","Acute coronary syndrome","influenza vaccination","2026-05-16",{"date":648,"type":57},{"date":701,"type":57},"2026-01-01",{"date":703,"type":24},"2026-10-10",{"name":705,"class":64},"University of Brawijaya",{"id":707,"slug":708,"hasResults":12,"nctId":709,"briefTitle":710,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":19,"minAge":136,"maxAge":166,"enrollmentInfo":712,"targetDuration":4,"studyType":139,"phases":713,"briefSummary":714,"conditions":715,"keywords":4,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":717,"lastUpdatePostDateStruct":718,"startDateStruct":720,"completionDateStruct":721,"leadSponsor":723,"locationsCount":4},"100638894","the-effectiveness-of-different-nebulized-solutions-on-airway-clearance-function-in-patients-with-pneumonia-100638894","NCT07586345","The Effectiveness of Different Nebulized Solutions on Airway Clearance Function in Patients With Pneumonia","Inclusion Criteria:\n\n1. Diagnosed with pneumonia, defined by ICD-10 codes, including:\n\n   J18: Pneumonia, unspecified organism J180: Bronchopneumonia, unspecified organism J181: Lobar pneumonia, unspecified organism J182: Hypostatic pneumonia, unspecified organism J188: Other pneumonia, unspecified organism J189: Pneumonia, unspecified organism\n2. Aged 18-100 years\n3. Clinical respiratory score \\> 3\n4. Patients unable to expectorate sputum spontaneously and requiring assisted suctioning\n\nExclusion Criteria:\n\n1. Diagnosis of influenza-associated pneumonia, defined by ICD-10 codes, including:\n\n   J09X1: Influenza due to identified novel influenza A virus with pneumonia J1001: Influenza due to other identified influenza virus with the same identified influenza viral pneumonia J100: Influenza due to other identified influenza virus with pneumonia\n2. Diagnosis of COVID-19 infection, defined by ICD-10 code:\n\n   U07.1: COVID-19, virus identified\n3. History of chronic obstructive pulmonary disease (COPD) (ICD-10 code: J44)\n4. History of lung cancer or metastatic cancer involving the lungs\n5. Current use of bronchodilators\n6. Patients requiring oral suctioning only\n7. Oxygen therapy with a flow rate \\> 10 L\u002Fmin\n8. Clinical respiratory score \\> 8 (Table 2)",{"count":323,"type":24},[141],"Pneumonia is a significant global and national health issue, particularly posing a notable threat to elderly population. Accumulation of sputum in pneumonia patients often results in impaired airway clearance, negatively impacting disease management and recovery. Clinically, nebulization therapy is widely employed to facilitate sputum clearance; however, evidence regarding the comparative effectiveness of different nebulized solution concentrations remains limited and inconsistent. Therefore, this study aims to evaluate and compare the clinical effects of nebulized solutions with various osmotic concentrations (3% hypertonic saline, 0.9% normal saline, 0.45% hypotonic saline, and distilled water) on airway clearance in patients with pneumonia. A randomized, double-blind controlled trial design will be used, recruiting 80 patients with pneumonia from a regional teaching hospital in northern Taiwan. Participants will be randomly assigned into four groups, receiving nebulized therapy four times daily over a period of seven days. This study outcome including the length of hospital stay, venous blood gas analysis, routine sputum examination, and arterial oxygen content. The findings of this the study are anticipated to provide evidence-based recommendations for the clinical application of nebulized solutions with different concentrations, aiming to enhance airway clearance efficiency, improve clinical care outcomes for pneumonia patients, and serve as a practical reference for healthcare professionals.",[41,716],"Airway Clearance","2026-05-12",{"date":719,"type":57},"2026-05-14",{"date":230,"type":24},{"date":722,"type":24},"2027-12-31",{"name":724,"class":64},"Chen, Yao-Hsiang"]